SZSiyuan Zou

Siyuan Zou

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Siyuan Zou has a total of 10 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Assessing and engineering the IscB–ωRNA system for programmed genome editing

    by Hao Yan, Xiaoqing Tan, Siyuan Zou, Yihong Sun, Ailong Ke, Weixin Tang

    OMEGA RNA (ωRNA)-guided endonuclease IscB, the evolutionary ancestor of Cas9, is an attractive system for in vivo genome editing because of its compact size and mechanistic resemblance to Cas9. However, wild-type IscB–ωRNA systems show limited activity in human cells. Here we report enhanced OgeuIscB, which, with eight amino acid substitutions, displayed a fourfold increase in in vitro DNA-binding affinity and a 30.4-fold improvement in insertion–deletion (indel) formation efficiency in human cells. Paired with structure-guided ωRNA engineering, the enhanced OgeuIscB–ωRNA systems efficiently edited the human genome across 26 target sites, attaining up to 87.3% indel and 62.2% base-editing frequencies. Both wild-type and engineered OgeuIscB–ωRNA showed moderate fidelity in editing the human genome, with off-target profiles revealing key determinants of target selection including an NARR target-adjacent motif (TAM) and the TAM-proximal 14 nucleotides in the R-loop. Collectively, our engineered OgeuIscB–ωRNA systems are programmable, potent and sufficiently specific for human genome editing.


  • Open Access

    Author Correction: An engineered hypercompact CRISPR-Cas12f system with boosted gene-editing activity

    by Tong Wu, Chang Liu, Siyuan Zou, Ruitu Lyu, Bowei Yang, Hao Yan, Minglei Zhao, Weixin Tang


  • An engineered hypercompact CRISPR-Cas12f system with boosted gene-editing activity

    by Tong Wu, Chang Liu, Siyuan Zou, Ruitu Lyu, Bowei Yang, Hao Yan, Minglei Zhao, Weixin Tang

    Compact CRISPR-Cas systems offer versatile treatment options for genetic disorders, but their application is often limited by modest gene-editing activity. Here we present enAsCas12f, an engineered RNA-guided DNA endonuclease up to 11.3-fold more potent than its parent protein, AsCas12f, and one-third of the size of SpCas9. enAsCas12f shows higher DNA cleavage activity than wild-type AsCas12f in vitro and functions broadly in human cells, delivering up to 69.8% insertions and deletions at user-specified genomic loci. Minimal off-target editing is observed with enAsCas12f, suggesting that boosted on-target activity does not impair genome-wide specificity. We determine the cryo-electron microscopy (cryo-EM) structure of the AsCas12f–sgRNA–DNA complex at a resolution of 2.9 Å, which reveals dimerization-mediated substrate recognition and cleavage. Structure-guided single guide RNA (sgRNA) engineering leads to sgRNA-v2, which is 33% shorter than the full-length sgRNA, but with on par activity. Together, the engineered hypercompact AsCas12f system enables robust and faithful gene editing in mammalian cells.